Comprehensive Stock Comparison
Compare United Therapeutics Corporation (UTHR) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | UTHR | 10.6% revenue growth vs REGN's 1.0% |
| Value | UTHR | Lower P/E (16.9x vs 17.3x), PEG 0.88 vs 2.73 |
| Quality / Margins | UTHR | 41.9% net margin vs REGN's 31.4% |
| Stability / Safety | UTHR | Beta 0.43 vs REGN's 0.58 |
| Dividends | REGN | 0.4% yield; 1-year raise streak; UTHR pays no meaningful dividend |
| Momentum (1Y) | UTHR | +57.4% vs REGN's +12.4% |
| Efficiency (ROA) | UTHR | 16.9% ROA vs REGN's 11.1%, ROIC 21.1% vs 12.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Valuation efficiency (growth/$)
Defensive / Recession hedge
Business Model
What each company does and how it makes money
United Therapeutics is a biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension and other rare diseases. It generates revenue primarily from its portfolio of PAH treatments — including Remodulin, Tyvaso, and Orenitram — which account for the vast majority of its sales. The company's competitive advantage lies in its deep expertise in prostacyclin therapies and its vertically integrated manufacturing capabilities for complex drug delivery systems.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
UTHR leads in 4 of 6 categories — strongest in Financial Metrics and Valuation Metrics. 1 category is tied.
Financial Metrics (TTM)
REGN is the larger business by revenue, generating $14.3B annually — 4.5x UTHR's $3.2B. UTHR is the more profitable business, keeping 41.9% of every revenue dollar as net income compared to REGN's 31.4%. On growth, UTHR holds the edge at +7.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | UTHRUnited Therapeuti… | REGNRegeneron Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $3.2B | $14.3B |
| EBITDAEarnings before interest/tax | $1.6B | $4.2B |
| Net IncomeAfter-tax profit | $1.3B | $4.5B |
| Free Cash FlowCash after capex | $1.0B | $3.2B |
| Gross MarginGross profit ÷ Revenue | +87.9% | +86.3% |
| Operating MarginEBIT ÷ Revenue | +46.9% | +25.7% |
| Net MarginNet income ÷ Revenue | +41.9% | +31.4% |
| FCF MarginFCF ÷ Revenue | +32.7% | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.4% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +23.7% | -2.5% |
Valuation Metrics
At 18.1x trailing earnings, UTHR trades at a 4% valuation discount to REGN's 18.8x P/E. Adjusting for growth (PEG ratio), UTHR offers better value at 0.94x vs REGN's 2.98x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | UTHRUnited Therapeuti… | REGNRegeneron Pharmac… |
|---|---|---|
| Market CapShares × price | $22.0B | $107.6B |
| Enterprise ValueMkt cap + debt − cash | $20.4B | $91.4B |
| Trailing P/EPrice ÷ TTM EPS | 18.09x | 18.84x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.90x | 17.25x |
| PEG RatioP/E ÷ EPS growth rate | 0.94x | 2.98x |
| EV / EBITDAEnterprise value multiple | 12.95x | 21.64x |
| Price / SalesMarket cap ÷ Revenue | 6.91x | 7.50x |
| Price / BookPrice ÷ Book value/share | 3.40x | 2.72x |
| Price / FCFMarket cap ÷ FCF | 21.13x | 26.36x |
Profitability & Efficiency
UTHR delivers a 18.8% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $14 for REGN.
| Metric | UTHRUnited Therapeuti… | REGNRegeneron Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | +18.8% | +14.4% |
| ROA (TTM)Return on assets | +16.9% | +11.1% |
| ROICReturn on invested capital | +21.1% | +12.4% |
| ROCEReturn on capital employed | +21.4% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 |
| Debt / EquityFinancial leverage | — | 0.09x |
| Net DebtTotal debt minus cash | -$1.6B | -$16.2B |
| Cash & Equiv.Liquid assets | $1.6B | $18.9B |
| Total DebtShort + long-term debt | $0 | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | 88.89x | 120.42x |
Total Returns (with DRIP)
A $10,000 investment in UTHR five years ago would be worth $29,421 today (with dividends reinvested), compared to $16,977 for REGN. Over the past 12 months, UTHR leads with a +57.4% total return vs REGN's +12.4%. The 3-year compound annual growth rate (CAGR) favors UTHR at 27.0% vs REGN's 1.1% — a key indicator of consistent wealth creation.
| Metric | UTHRUnited Therapeuti… | REGNRegeneron Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | +1.4% | +0.8% |
| 1-Year ReturnPast 12 months | +57.4% | +12.4% |
| 3-Year ReturnCumulative with dividends | +104.8% | +3.4% |
| 5-Year ReturnCumulative with dividends | +194.2% | +69.8% |
| 10-Year ReturnCumulative with dividends | +313.2% | +104.7% |
| CAGR (3Y)Annualised 3-year return | +27.0% | +1.1% |
Risk & Volatility
UTHR is the less volatile stock with a 0.43 beta — it tends to amplify market swings less than REGN's 0.58 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | UTHRUnited Therapeuti… | REGNRegeneron Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.43x | 0.58x |
| 52-Week HighHighest price in past year | $537.00 | $821.11 |
| 52-Week LowLowest price in past year | $266.98 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +93.8% | +95.2% |
| RSI (14)Momentum oscillator 0–100 | 58.6 | 49.1 |
| Avg Volume (50D)Average daily shares traded | 274K | 687K |
Analyst Outlook
Wall Street rates UTHR as "Buy" and REGN as "Buy". Consensus price targets imply 11.8% upside for UTHR (target: $563) vs 9.7% for REGN (target: $857). REGN is the only dividend payer here at 0.44% yield — a key consideration for income-focused portfolios.
| Metric | UTHRUnited Therapeuti… | REGNRegeneron Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $563.17 | $857.17 |
| # AnalystsCovering analysts | 30 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | 1 | 1 |
| Dividend / ShareAnnual DPS | — | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | +4.5% | +3.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| United Therapeutics… (UTHR) | 100 | 457.48 | +357.5% |
| Regeneron Pharmaceu… (REGN) | 100 | 162.46 | +62.5% |
United Therapeutics… (UTHR) returned +194% over 5 years vs Regeneron Pharmaceu… (REGN)'s +70%. A $10,000 investment in UTHR 5 years ago would be worth $29,421 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| United Therapeutics… (UTHR) | $1.6B | $3.2B | +99.1% |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
United Therapeutics Corporation's revenue grew from $1.6B (2016) to $3.2B (2025) — a 7.9% CAGR. Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| United Therapeutics… (UTHR) | 44.6% | 41.9% | -6.1% |
| Regeneron Pharmaceu… (REGN) | 18.4% | 31.4% | +70.5% |
United Therapeutics Corporation's net margin went from 45% (2016) to 42% (2025). Regeneron Pharmaceuticals, Inc.'s net margin went from 18% (2016) to 31% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| United Therapeutics… (UTHR) | 15.9 | 17.5 | +10.1% |
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
United Therapeutics Corporation has traded in a 8x–22x P/E range over 8 years; current trailing P/E is ~18x. Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| United Therapeutics… (UTHR) | 15.25 | 27.86 | +82.7% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
United Therapeutics Corporation's EPS grew from $15.25 (2016) to $27.86 (2025) — a 7% CAGR. Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
United Therapeutics Corporation generated $1B FCF in 2025 (+118% vs 2021). Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021).
UTHR vs REGN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is UTHR or REGN a better buy right now?
United Therapeutics Corporation (UTHR) offers the better valuation at 18.1x trailing P/E (16.9x forward), making it the more compelling value choice. Analysts rate United Therapeutics Corporation (UTHR) a "Buy" — based on 30 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — UTHR or REGN?
On trailing P/E, United Therapeutics Corporation (UTHR) is the cheapest at 18.1x versus Regeneron Pharmaceuticals, Inc. at 18.8x. On forward P/E, United Therapeutics Corporation is actually cheaper at 16.9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: United Therapeutics Corporation wins at 0.88x versus Regeneron Pharmaceuticals, Inc.'s 2.73x — a PEG below 1.0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — UTHR or REGN?
Over the past 5 years, United Therapeutics Corporation (UTHR) delivered a total return of +194.2%, compared to +69.8% for Regeneron Pharmaceuticals, Inc. (REGN). A $10,000 investment in UTHR five years ago would be worth approximately $29K today (assuming dividends reinvested). Over 10 years, the gap is even starker: UTHR returned +313.2% versus REGN's +104.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — UTHR or REGN?
By beta (market sensitivity over 5 years), United Therapeutics Corporation (UTHR) is the lower-risk stock at 0.43β versus Regeneron Pharmaceuticals, Inc.'s 0.58β — meaning REGN is approximately 33% more volatile than UTHR relative to the S&P 500.
05Which has better profit margins — UTHR or REGN?
United Therapeutics Corporation (UTHR) is the more profitable company, earning 41.9% net margin versus 31.4% for Regeneron Pharmaceuticals, Inc. — meaning it keeps 41.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTHR leads at 46.9% versus 25.7% for REGN. At the gross margin level — before operating expenses — UTHR leads at 87.9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is UTHR or REGN more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, United Therapeutics Corporation (UTHR) is the more undervalued stock at a PEG of 0.88x versus Regeneron Pharmaceuticals, Inc.'s 2.73x. A PEG below 1.0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, United Therapeutics Corporation (UTHR) trades at 16.9x forward P/E versus 17.3x for Regeneron Pharmaceuticals, Inc. — 0.4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for UTHR: 11.8% to $563.17.
07Which pays a better dividend — UTHR or REGN?
In this comparison, REGN (0.4% yield) pays a dividend. UTHR does not pay a meaningful dividend and should not be held primarily for income.
08Is UTHR or REGN better for a retirement portfolio?
For long-horizon retirement investors, United Therapeutics Corporation (UTHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.43), +313.2% 10Y return). Both have compounded well over 10 years (UTHR: +313.2%, REGN: +104.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between UTHR and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.